[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573565":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":11,"centralContacts":32,"locations":11,"responsibleParty":38,"collaborators":11,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":11,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":11,"enrollmentInfo":49,"targetDuration":11,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":11,"overallStatus":58,"whyStopped":11,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":11},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"AD-2281 + AD-2282","EXPERIMENTAL",null,[13,14],"Drug: AD-2281","Drug: AD-2282",{"label":16,"type":17,"description":11,"interventionNames":18},"AD-2281 + Placebo of AD-2282","ACTIVE_COMPARATOR",[13,19],"Drug: Placebo of AD-2282",[21,26,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","AD-2281","PO, Once daily, 8weeks",[9,16],{"type":22,"name":27,"description":24,"armGroupLabels":28,"otherNames":11},"AD-2282",[9],{"type":22,"name":30,"description":24,"armGroupLabels":31,"otherNames":11},"Placebo of AD-2282",[16],[33],{"name":34,"role":35,"phone":36,"phoneExt":11,"email":37},"JeongEun Park","CONTACT","+82-31-891-6989","parkje@addpharma.co.kr",{"type":39,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100573565","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-co-administration-of-ad-2281-and-ad-2282-100573565",false,"NCT06747936","A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282","A Randomized, Double-blind, Active-controlled, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combined Administration of AD-2281 and AD-2282 in Patients with Primary Hypercholesterolemia.","Inclusion Criteria:\n\n* Signed informed consent\n* Patients with Primary Hypercholesterolemia\n* Other inclusions applied\n\nExclusion Criteria:\n\n* Patients with Secondary Hypercholesterolemia\n* Other exclusions applied","ALL","19 Years",{"count":50,"type":51},110,"ESTIMATED","INTERVENTIONAL",[54],"PHASE3","The purpose of this study is to evaluate the efficacy and safetyof co-administration of AD-2281 and AD-2282 in patients with Primary Hypercholesterolemia",[57],"Primary Hypercholesterolemia","NOT_YET_RECRUITING","2025-02-02",{"date":61,"type":62},"2025-02-04","ACTUAL",{"date":64,"type":51},"2025-02",{"date":66,"type":51},"2026-12",{"name":5,"class":6}]